β-catenin mediates monocrotaline-induced pulmonary hypertension via glycolysis in rats

Metabolic abnormalities and immune inflammation are deeply involved in pulmonary vascular remodelling and the development of pulmonary hypertension (PH). However, the regulatory mechanisms of glycolysis in macrophages are still elusive. Cumulative evidence indicates that β-catenin plays a crucial ro...

Full description

Saved in:
Bibliographic Details
Published inBMC cardiovascular disorders Vol. 24; no. 1; pp. 381 - 14
Main Authors Meng, Hui, Deng, Yan, Liao, Juan, Wu, Dan-dan, Li, Li-xiang, Chen, Xing, Lan, Wei‑Fang
Format Journal Article
LanguageEnglish
Published England BioMed Central 23.07.2024
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Metabolic abnormalities and immune inflammation are deeply involved in pulmonary vascular remodelling and the development of pulmonary hypertension (PH). However, the regulatory mechanisms of glycolysis in macrophages are still elusive. Cumulative evidence indicates that β-catenin plays a crucial role in metabolic reprogramming. This study aimed to investigate the effect of β-catenin on macrophage glycolysis in PH. LPS-induced BMDMs were generated via in vitro experiments. A monocrotaline (MCT)-induced PH rat model was established, and the β-catenin inhibitor XAV939 was administered in vivo. The role of β-catenin in glycolysis was analysed. The degree of pulmonary vascular remodelling was measured. β-catenin was significantly increased in both in vitro and in vivo models. In LPS-induced BMDMs, β-catenin increased the levels of hexokinase 2 (HK2), phosphofructokinase (PFK), M2-pyruvate kinase (PKM2), lactate dehydrogenase (LDH), and lactate (LA) and the expression of inflammatory cytokines and promoted PASMC proliferation and migration in vitro. XAV939 decreased the level of glycolysis and downregulated the expression of inflammatory cytokines in vivo. MCT promoted pulmonary arterial structural remodelling and right ventricular hypertrophy, and XAV939 alleviated these changes. Our findings suggest that β-catenin is involved in the development of PH by promoting glycolysis and the inflammatory response in macrophages. Inhibition of β-catenin could improve the progression of PH.
AbstractList Metabolic abnormalities and immune inflammation are deeply involved in pulmonary vascular remodelling and the development of pulmonary hypertension (PH). However, the regulatory mechanisms of glycolysis in macrophages are still elusive. Cumulative evidence indicates that β-catenin plays a crucial role in metabolic reprogramming. This study aimed to investigate the effect of β-catenin on macrophage glycolysis in PH. LPS-induced BMDMs were generated via in vitro experiments. A monocrotaline (MCT)-induced PH rat model was established, and the β-catenin inhibitor XAV939 was administered in vivo. The role of β-catenin in glycolysis was analysed. The degree of pulmonary vascular remodelling was measured. β-catenin was significantly increased in both in vitro and in vivo models. In LPS-induced BMDMs, β-catenin increased the levels of hexokinase 2 (HK2), phosphofructokinase (PFK), M2-pyruvate kinase (PKM2), lactate dehydrogenase (LDH), and lactate (LA) and the expression of inflammatory cytokines and promoted PASMC proliferation and migration in vitro. XAV939 decreased the level of glycolysis and downregulated the expression of inflammatory cytokines in vivo. MCT promoted pulmonary arterial structural remodelling and right ventricular hypertrophy, and XAV939 alleviated these changes. Our findings suggest that β-catenin is involved in the development of PH by promoting glycolysis and the inflammatory response in macrophages. Inhibition of β-catenin could improve the progression of PH.
BackgroundMetabolic abnormalities and immune inflammation are deeply involved in pulmonary vascular remodelling and the development of pulmonary hypertension (PH). However, the regulatory mechanisms of glycolysis in macrophages are still elusive. Cumulative evidence indicates that β-catenin plays a crucial role in metabolic reprogramming. This study aimed to investigate the effect of β-catenin on macrophage glycolysis in PH.MethodsLPS-induced BMDMs were generated via in vitro experiments. A monocrotaline (MCT)-induced PH rat model was established, and the β-catenin inhibitor XAV939 was administered in vivo. The role of β-catenin in glycolysis was analysed. The degree of pulmonary vascular remodelling was measured.Resultsβ-catenin was significantly increased in both in vitro and in vivo models. In LPS-induced BMDMs, β-catenin increased the levels of hexokinase 2 (HK2), phosphofructokinase (PFK), M2-pyruvate kinase (PKM2), lactate dehydrogenase (LDH), and lactate (LA) and the expression of inflammatory cytokines and promoted PASMC proliferation and migration in vitro. XAV939 decreased the level of glycolysis and downregulated the expression of inflammatory cytokines in vivo. MCT promoted pulmonary arterial structural remodelling and right ventricular hypertrophy, and XAV939 alleviated these changes.ConclusionsOur findings suggest that β-catenin is involved in the development of PH by promoting glycolysis and the inflammatory response in macrophages. Inhibition of β-catenin could improve the progression of PH.
Abstract Background Metabolic abnormalities and immune inflammation are deeply involved in pulmonary vascular remodelling and the development of pulmonary hypertension (PH). However, the regulatory mechanisms of glycolysis in macrophages are still elusive. Cumulative evidence indicates that β-catenin plays a crucial role in metabolic reprogramming. This study aimed to investigate the effect of β-catenin on macrophage glycolysis in PH. Methods LPS-induced BMDMs were generated via in vitro experiments. A monocrotaline (MCT)-induced PH rat model was established, and the β-catenin inhibitor XAV939 was administered in vivo. The role of β-catenin in glycolysis was analysed. The degree of pulmonary vascular remodelling was measured. Results β-catenin was significantly increased in both in vitro and in vivo models. In LPS-induced BMDMs, β-catenin increased the levels of hexokinase 2 (HK2), phosphofructokinase (PFK), M2-pyruvate kinase (PKM2), lactate dehydrogenase (LDH), and lactate (LA) and the expression of inflammatory cytokines and promoted PASMC proliferation and migration in vitro. XAV939 decreased the level of glycolysis and downregulated the expression of inflammatory cytokines in vivo. MCT promoted pulmonary arterial structural remodelling and right ventricular hypertrophy, and XAV939 alleviated these changes. Conclusions Our findings suggest that β-catenin is involved in the development of PH by promoting glycolysis and the inflammatory response in macrophages. Inhibition of β-catenin could improve the progression of PH.
Metabolic abnormalities and immune inflammation are deeply involved in pulmonary vascular remodelling and the development of pulmonary hypertension (PH). However, the regulatory mechanisms of glycolysis in macrophages are still elusive. Cumulative evidence indicates that β-catenin plays a crucial role in metabolic reprogramming. This study aimed to investigate the effect of β-catenin on macrophage glycolysis in PH.BACKGROUNDMetabolic abnormalities and immune inflammation are deeply involved in pulmonary vascular remodelling and the development of pulmonary hypertension (PH). However, the regulatory mechanisms of glycolysis in macrophages are still elusive. Cumulative evidence indicates that β-catenin plays a crucial role in metabolic reprogramming. This study aimed to investigate the effect of β-catenin on macrophage glycolysis in PH.LPS-induced BMDMs were generated via in vitro experiments. A monocrotaline (MCT)-induced PH rat model was established, and the β-catenin inhibitor XAV939 was administered in vivo. The role of β-catenin in glycolysis was analysed. The degree of pulmonary vascular remodelling was measured.METHODSLPS-induced BMDMs were generated via in vitro experiments. A monocrotaline (MCT)-induced PH rat model was established, and the β-catenin inhibitor XAV939 was administered in vivo. The role of β-catenin in glycolysis was analysed. The degree of pulmonary vascular remodelling was measured.β-catenin was significantly increased in both in vitro and in vivo models. In LPS-induced BMDMs, β-catenin increased the levels of hexokinase 2 (HK2), phosphofructokinase (PFK), M2-pyruvate kinase (PKM2), lactate dehydrogenase (LDH), and lactate (LA) and the expression of inflammatory cytokines and promoted PASMC proliferation and migration in vitro. XAV939 decreased the level of glycolysis and downregulated the expression of inflammatory cytokines in vivo. MCT promoted pulmonary arterial structural remodelling and right ventricular hypertrophy, and XAV939 alleviated these changes.RESULTSβ-catenin was significantly increased in both in vitro and in vivo models. In LPS-induced BMDMs, β-catenin increased the levels of hexokinase 2 (HK2), phosphofructokinase (PFK), M2-pyruvate kinase (PKM2), lactate dehydrogenase (LDH), and lactate (LA) and the expression of inflammatory cytokines and promoted PASMC proliferation and migration in vitro. XAV939 decreased the level of glycolysis and downregulated the expression of inflammatory cytokines in vivo. MCT promoted pulmonary arterial structural remodelling and right ventricular hypertrophy, and XAV939 alleviated these changes.Our findings suggest that β-catenin is involved in the development of PH by promoting glycolysis and the inflammatory response in macrophages. Inhibition of β-catenin could improve the progression of PH.CONCLUSIONSOur findings suggest that β-catenin is involved in the development of PH by promoting glycolysis and the inflammatory response in macrophages. Inhibition of β-catenin could improve the progression of PH.
ArticleNumber 381
Author Lan, Wei‑Fang
Liao, Juan
Wu, Dan-dan
Chen, Xing
Deng, Yan
Meng, Hui
Li, Li-xiang
Author_xml – sequence: 1
  givenname: Hui
  surname: Meng
  fullname: Meng, Hui
– sequence: 2
  givenname: Yan
  orcidid: 0000-0003-3727-6986
  surname: Deng
  fullname: Deng, Yan
– sequence: 3
  givenname: Juan
  surname: Liao
  fullname: Liao, Juan
– sequence: 4
  givenname: Dan-dan
  surname: Wu
  fullname: Wu, Dan-dan
– sequence: 5
  givenname: Li-xiang
  surname: Li
  fullname: Li, Li-xiang
– sequence: 6
  givenname: Xing
  surname: Chen
  fullname: Chen, Xing
– sequence: 7
  givenname: Wei‑Fang
  surname: Lan
  fullname: Lan, Wei‑Fang
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39044140$$D View this record in MEDLINE/PubMed
BookMark eNp9kstuFDEQRS0URB7wAyxQS2zYNPjVfqwQinhEisQmEkur2nZPPPLYg90dafJZfAjfhJlJUJIFK5dc9x6VXfcUHaWcPEKvCX5PiBIfKqFK0h5T3mOOMe5vn6ETwiXpKRXk6EF9jE5rXWNMpML6BTpmGnNOOD5BP37_6i3MPoXUbbwLrazdJqdsS54hhuT7kNxiveu2S2wNKLvuerf1pXlqyKm7CdCt4s7muKuhdo1TYK4v0fMJYvWv7s4zdPXl89X5t_7y-9eL80-XveVazv00SM8knsB5pck0TRiPhDirhlHZUbBxpN6LiQ_UAbN2oNpxBhQs04MQkp2hiwPWZVibbQmbNp_JEMz-IpeVgTIHG70ZhbbKSiCyMRxV4KyjI6GjdpRZEI318cDaLmP7CuvTXCA-gj7upHBtVvnGEEIFZ5o1wrs7Qsk_F19nswnV-hgh-bxUw7DimGGphyZ9-0S6zktJ7auaSrfFarl_3puHI_2b5X5_TaAOgrauWoufjA0zzG0vbcIQDcHmb1TMISqmRcXso2Jum5U-sd7T_2P6AxazxKE
CitedBy_id crossref_primary_10_3389_fcvm_2025_1554702
Cites_doi 10.1515/revneuro-2017-0032
10.1161/CIRCULATIONAHA.117.029930
10.1186/s13046-020-01808-3
10.3390/cancers11070904
10.1038/s41467-019-11662-3
10.1016/j.molimm.2020.02.017
10.3389/fphar.2019.00128
10.1016/j.immuni.2021.04.001
10.1186/s12929-018-0418-4
10.1186/s13046-021-02229-6
10.1111/imr.12608
10.1161/CIRCULATIONAHA.117.029254
10.1038/emboj.2012.150
10.1007/s11239-020-02356-5
10.15252/embj.201488598
10.1186/s13046-018-0673-y
10.1073/pnas.1821401116
10.1136/thoraxjnl-2016-209753
10.1136/bmj.j5492
10.1016/j.cell.2017.05.016
10.1038/s41392-021-00762-6
10.1152/ajplung.00260.2003
10.1038/s41598-022-06848-7
10.3389/fimmu.2023.1152881
10.1183/13993003.01913-2018
10.3892/mmr.2021.11833
10.1111/febs.15327
10.1186/s13287-022-02836-w
10.1161/CIRCULATIONAHA.117.028034
10.1016/j.chest.2017.10.007
10.1016/S2213-2600(15)00543-3
10.1536/ihj.19-096
10.1172/JCI120847
10.1016/j.imbio.2023.152345
ContentType Journal Article
Copyright 2024. The Author(s).
2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2024 2024
Copyright_xml – notice: 2024. The Author(s).
– notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2024 2024
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QP
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12872-024-04000-z
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Calcium & Calcified Tissue Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE
Publicly Available Content Database

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals (ODIN)
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-2261
EndPage 14
ExternalDocumentID oai_doaj_org_article_b69c8c7a179d4d28adcd2b12b9d23ca6
PMC11264393
39044140
10_1186_s12872_024_04000_z
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Beijing China
China
GeographicLocations_xml – name: China
– name: Beijing China
GrantInformation_xml – fundername: Guangxi medical "139" Program for Training High-level Backbone Talents
  grantid: G201903053
– fundername: the Precision Medicine Foundation of Guangxi Key Laboratory of Cardio-cerebrovascular Disease
  grantid: GXXNXG202001
– fundername: the National Natural Science Foundation of China
  grantid: 82060051
– fundername: the projects of Guangxi Medical and Health Appropriate Technology Development and Promotion Application
  grantid: S2020030
GroupedDBID ---
0R~
23N
2WC
53G
5VS
6J9
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
ECGQY
EMB
EMOBN
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
UKHRP
W2D
WOQ
WOW
XSB
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
3V.
7QP
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c497t-f57e370fade891fff00b11dc85b8cb63bb2ee6f452da3cc529d43a2ac3956673
IEDL.DBID M48
ISSN 1471-2261
IngestDate Wed Aug 27 01:27:13 EDT 2025
Thu Aug 21 18:32:53 EDT 2025
Fri Jul 11 11:06:06 EDT 2025
Sat Jul 26 02:43:44 EDT 2025
Mon Jul 21 05:39:34 EDT 2025
Thu Apr 24 23:10:59 EDT 2025
Tue Jul 01 02:38:11 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Glycolysis
β-catenin
Macrophages
NLRP3 inflammasome
Monocrotaline
Pulmonary hypertension
Language English
License 2024. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c497t-f57e370fade891fff00b11dc85b8cb63bb2ee6f452da3cc529d43a2ac3956673
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-3727-6986
OpenAccessLink https://www.proquest.com/docview/3091289767?pq-origsite=%requestingapplication%
PMID 39044140
PQID 3091289767
PQPubID 44077
PageCount 14
ParticipantIDs doaj_primary_oai_doaj_org_article_b69c8c7a179d4d28adcd2b12b9d23ca6
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11264393
proquest_miscellaneous_3084030795
proquest_journals_3091289767
pubmed_primary_39044140
crossref_citationtrail_10_1186_s12872_024_04000_z
crossref_primary_10_1186_s12872_024_04000_z
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-07-23
PublicationDateYYYYMMDD 2024-07-23
PublicationDate_xml – month: 07
  year: 2024
  text: 2024-07-23
  day: 23
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle BMC cardiovascular disorders
PublicationTitleAlternate BMC Cardiovasc Disord
PublicationYear 2024
Publisher BioMed Central
BMC
Publisher_xml – name: BioMed Central
– name: BMC
References S Dong (4000_CR34) 2022; 41
MK Culley (4000_CR26) 2018; 128
SJ Dumas (4000_CR7) 2018; 137
S-S Xie (4000_CR11) 2022; 12
T Valenta (4000_CR16) 2012; 31
F-Y Zhao (4000_CR22) 2021; 23
J Weatherald (4000_CR1) 2018; 137
B Zhu (4000_CR33) 2021; 54
Q Fan (4000_CR14) 2018; 37
A Vallée (4000_CR17) 2017; 29
G Simonneau (4000_CR2) 2019; 53
MM Hughes (4000_CR27) 2018; 281
M-Q Zhang (4000_CR9) 2023; 14
T Kondo (4000_CR4) 2019; 81
Y Fang (4000_CR29) 2019; 10
T Thenappan (4000_CR5) 2018; 360
G Soto-Heredero (4000_CR8) 2020; 287
D Wu (4000_CR12) 2023; 228
L Huang (4000_CR24) 2020; 121
J Liu (4000_CR28) 2022; 7
Y Jiang (4000_CR30) 2021; 40
R Nusse (4000_CR13) 2017; 169
MM Hoeper (4000_CR3) 2016; 4
P Caruso (4000_CR25) 2017; 136
HA Baarsma (4000_CR32) 2017; 72
Y Cao (4000_CR6) 2019; 116
Y Deng (4000_CR10) 2019; 10
L Deng (4000_CR15) 2022; 13
S El-Sahli (4000_CR18) 2019; 11
NS Hill (4000_CR19) 2017; 152
4000_CR35
W Feng (4000_CR20) 2020; 61
M Zeng (4000_CR21) 2021; 52
4000_CR31
C Lombry (4000_CR23) 2004; 286
References_xml – volume: 29
  start-page: 71
  year: 2017
  ident: 4000_CR17
  publication-title: Rev Neurosci
  doi: 10.1515/revneuro-2017-0032
– volume: 137
  start-page: 2371
  year: 2018
  ident: 4000_CR7
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.117.029930
– volume: 40
  start-page: 13
  year: 2021
  ident: 4000_CR30
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-020-01808-3
– volume: 11
  start-page: 904
  year: 2019
  ident: 4000_CR18
  publication-title: Cancers
  doi: 10.3390/cancers11070904
– volume: 10
  start-page: 3981
  year: 2019
  ident: 4000_CR29
  publication-title: Nat Commun
  doi: 10.1038/s41467-019-11662-3
– volume: 121
  start-page: 186
  year: 2020
  ident: 4000_CR24
  publication-title: Mol Immunol
  doi: 10.1016/j.molimm.2020.02.017
– volume: 10
  start-page: 128
  year: 2019
  ident: 4000_CR10
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2019.00128
– volume: 54
  start-page: 1200
  year: 2021
  ident: 4000_CR33
  publication-title: Immunity
  doi: 10.1016/j.immuni.2021.04.001
– ident: 4000_CR35
  doi: 10.1186/s12929-018-0418-4
– volume: 41
  start-page: 15
  year: 2022
  ident: 4000_CR34
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-021-02229-6
– volume: 281
  start-page: 88
  year: 2018
  ident: 4000_CR27
  publication-title: Immunol Rev
  doi: 10.1111/imr.12608
– volume: 137
  start-page: 693
  year: 2018
  ident: 4000_CR1
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.117.029254
– volume: 31
  start-page: 2714
  year: 2012
  ident: 4000_CR16
  publication-title: EMBO J
  doi: 10.1038/emboj.2012.150
– volume: 52
  start-page: 454
  year: 2021
  ident: 4000_CR21
  publication-title: J Thromb Thrombolysis
  doi: 10.1007/s11239-020-02356-5
– ident: 4000_CR31
  doi: 10.15252/embj.201488598
– volume: 37
  start-page: 9
  year: 2018
  ident: 4000_CR14
  publication-title: J Exp Clin Cancer Res CR
  doi: 10.1186/s13046-018-0673-y
– volume: 116
  start-page: 13394
  year: 2019
  ident: 4000_CR6
  publication-title: Proc Natl Acad Sci
  doi: 10.1073/pnas.1821401116
– volume: 72
  start-page: 746
  year: 2017
  ident: 4000_CR32
  publication-title: Thorax
  doi: 10.1136/thoraxjnl-2016-209753
– volume: 360
  start-page: j5492
  year: 2018
  ident: 4000_CR5
  publication-title: BMJ
  doi: 10.1136/bmj.j5492
– volume: 169
  start-page: 985
  year: 2017
  ident: 4000_CR13
  publication-title: Cell
  doi: 10.1016/j.cell.2017.05.016
– volume: 81
  start-page: 19
  year: 2019
  ident: 4000_CR4
  publication-title: Nagoya J Med Sci
– volume: 7
  start-page: 3
  year: 2022
  ident: 4000_CR28
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-021-00762-6
– volume: 286
  start-page: L1002
  year: 2004
  ident: 4000_CR23
  publication-title: Am J Physiol Lung Cell Mol Physiol
  doi: 10.1152/ajplung.00260.2003
– volume: 12
  start-page: 3056
  year: 2022
  ident: 4000_CR11
  publication-title: Sci Rep
  doi: 10.1038/s41598-022-06848-7
– volume: 14
  start-page: 1152881
  year: 2023
  ident: 4000_CR9
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2023.1152881
– volume: 53
  start-page: 1801913
  year: 2019
  ident: 4000_CR2
  publication-title: Eur Respir J
  doi: 10.1183/13993003.01913-2018
– volume: 23
  start-page: 39
  year: 2021
  ident: 4000_CR22
  publication-title: Mol Med Rep
  doi: 10.3892/mmr.2021.11833
– volume: 287
  start-page: 3350
  year: 2020
  ident: 4000_CR8
  publication-title: FEBS J
  doi: 10.1111/febs.15327
– volume: 13
  start-page: 162
  year: 2022
  ident: 4000_CR15
  publication-title: Stem Cell Res Ther
  doi: 10.1186/s13287-022-02836-w
– volume: 136
  start-page: 2451
  year: 2017
  ident: 4000_CR25
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.117.028034
– volume: 152
  start-page: 1106
  year: 2017
  ident: 4000_CR19
  publication-title: Chest
  doi: 10.1016/j.chest.2017.10.007
– volume: 4
  start-page: 306
  year: 2016
  ident: 4000_CR3
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(15)00543-3
– volume: 61
  start-page: 160
  year: 2020
  ident: 4000_CR20
  publication-title: Int Heart J
  doi: 10.1536/ihj.19-096
– volume: 128
  start-page: 3704
  year: 2018
  ident: 4000_CR26
  publication-title: J Clin Invest
  doi: 10.1172/JCI120847
– volume: 228
  start-page: 152345
  year: 2023
  ident: 4000_CR12
  publication-title: Immunobiology
  doi: 10.1016/j.imbio.2023.152345
SSID ssj0017809
Score 2.358012
Snippet Metabolic abnormalities and immune inflammation are deeply involved in pulmonary vascular remodelling and the development of pulmonary hypertension (PH)....
BackgroundMetabolic abnormalities and immune inflammation are deeply involved in pulmonary vascular remodelling and the development of pulmonary hypertension...
Abstract Background Metabolic abnormalities and immune inflammation are deeply involved in pulmonary vascular remodelling and the development of pulmonary...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 381
SubjectTerms Animals
beta Catenin - metabolism
Bone marrow
Cell Movement - drug effects
Cell Proliferation - drug effects
Cytokines
Disease Models, Animal
Enzymes
Glycolysis
Glycolysis - drug effects
Heart
Hemodynamics
Hexokinase
Hypertension
Hypertension, Pulmonary - chemically induced
Hypertension, Pulmonary - metabolism
Hypertension, Pulmonary - physiopathology
Hypertrophy
Hypertrophy, Right Ventricular - chemically induced
Hypertrophy, Right Ventricular - metabolism
Hypertrophy, Right Ventricular - physiopathology
Inflammation
Inflammation Mediators - metabolism
L-Lactate dehydrogenase
Laboratory animals
Lactic acid
Leukocyte migration
Lipopolysaccharides
Lungs
Macrophages
Macrophages - drug effects
Macrophages - metabolism
Male
Metabolism
Monocrotaline
Myocytes, Smooth Muscle - drug effects
Myocytes, Smooth Muscle - metabolism
Myocytes, Smooth Muscle - pathology
NLRP3 inflammasome
Ostomy
Phosphofructokinase
Pulmonary arteries
Pulmonary Artery - drug effects
Pulmonary Artery - metabolism
Pulmonary Artery - pathology
Pulmonary Artery - physiopathology
Pulmonary hypertension
Pyruvate kinase
Pyruvic acid
Rats
Rats, Sprague-Dawley
Signal Transduction
Smooth muscle
Vascular Remodeling - drug effects
Veins & arteries
β-Catenin
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB6hHhCXikcpKQUZqbfKamIntnMERFUhlVNRe7P8bFdaeat9ILU_ix_Cb2LsZFddhOiFa-wkzsw3npnY_gbgSFhnu-ACjQzV0DrR0V4FRYWL6A24N778hzz_Js6-t1-vuqsHpb7ynrCBHngQ3IkVvVNOGgSObz1TxjvPbMNs7xl3ppBto89bJ1Pj-oFUdb8-IqPEyQJnYcko-iOaQVvT-y03VNj6_xZi_rlT8oHrOX0Ou2PMSD4OY30BT0J6CU_Px1XxV3D56yfNG5vSJJFyEgTDR4LwmuG7M8FhChQzb9ShJ7erKTaY-R25wQR0XravzxL5MTHkenqHoMgEJQSfg8BY7MHF6ZeLz2d0LJhAXdvLJY2dDFzW0fig-ibGWNe2abxTnVXOCm4tC0HEtmPecOc6hiLlhhnHMUsSkr-GnTRL4Q0QiZI1EUObXJxY2ahazHSCMqhLNFjbVNCsxafdSCaea1pMdUkqlNCDyDWKXBeR6_sKjjf33A5UGv_s_SlrZdMz02CXCwgOPYJDPwaOCg7XOtWjbS40R7hgmimFrODDphmtKi-VmBRmq9wHE1-c_vqugv0BApuR8L7GGLKtK1Bb4Nga6nZLmtwU5u58XgsjQH7wPz7uLTxjBdGSMn4IO8v5KrzDCGlp3xdj-A1P4BJi
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Zb9QwELagSIgX1HKGtihIvCGriZ34eEKAqCqk8lTEvlk-25VWznYPpPZn8UP4TYy93sAi1NfYcSYzn-fwMYPQW2as6b31OBAQQ2dZj6XwAjMbwBpQp11ehzz_ys6-dV8m_aQsuC3LscqtTsyK2g02rZGfUDBsEBxwxt_Pr3GqGpV2V0sJjfvoQUpdllDNJ2PA1XLRyO1FGcFOljAAJxisEk7QbfDtjjHKOfv_52j-e17yLwN0uo8eF8-x_rAR9QG65-MT9PC87I0_Rd9__cTpeFOcxjrfBwEnsgaqB_h2SnMYPYb4GyTp6vl6Bg16cVNfQRi6yIfYh1j_mOr6cnYD0EhpSmoYB-CxfIYuTj9ffDrDpWwCtp3kKxx67ilvgnZeyDaE0DSmbZ0VvRHWMGoM8Z6FridOU2t7Il1HNdGWQqzEOH2O9uIQ_UtUc6uZDuDgpBLFwgTRQbzjhQaJwrQ1bYXaLfuULSnFU2WLmcqhhWBqw3IFLFeZ5eq2Qu_Gd-abhBp39v6YpDL2TMmw84NhcanK3FKGSSss16BbXOeI0M46YlpipCMUfqFCR1uZqjJDl-oPnir0ZmyGuZU2THT0wzr1gfAXlKDsK_RiA4GREiob8CS7pkJiBxw7pO62xOlVzt-dbm2BH0hf3U3XIXpEMlY5JvQI7a0Wa38MHtDKvM4w_w1q0QjI
  priority: 102
  providerName: ProQuest
Title β-catenin mediates monocrotaline-induced pulmonary hypertension via glycolysis in rats
URI https://www.ncbi.nlm.nih.gov/pubmed/39044140
https://www.proquest.com/docview/3091289767
https://www.proquest.com/docview/3084030795
https://pubmed.ncbi.nlm.nih.gov/PMC11264393
https://doaj.org/article/b69c8c7a179d4d28adcd2b12b9d23ca6
Volume 24
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB71ISEuiDeBsgoSN2RI7MR2DgixqFWFtBWqWrHiEvmVdqVVUrK7Vbc_ix_Cb2LsTRYWrRCXHGLnNfON55vYngF4zbXRuTOOVBTVkBmek0I6Sbip0Bswq2z4Dzk64cfn2edxPt6BvtxRJ8DZ1tDO15M6b6dvb74vP6DBvw8GL_m7GY6xghL0NsRDMiG3u7CPnkn4igaj7PesgpBhyUeKAzJB2pH2m2i23mPDUYV8_ttI6N9rKf9wTkf34V7HKuOPKxg8gB1XP4Q7o27e_BF8_fmD-KVP9aSOw14RJJgxArDBZ_sUiLUjGJujlm18tZhig2qX8SWGqG1Y4N7U8fVExRfTJcLGpzCJ8T4IndljODs6PPt0TLqSCsRkhZiTKheOiaRS1skiraoqSXSaWiNzLY3mTGvqHK-ynFrFjMlpYTOmqDIM4ygu2BPYq5vaPYNYGMVVheTHly-WupIZxkJOKtQ2mrROI0h78ZWmSzfuq15MyxB2SF6uRF6iyMsg8vI2gjfra65WyTb-2XvotbLu6RNlhxNNe1F2dldqXhhphMJxx2aWSmWNpTqlurCU4SdEcNDrtOzBVzIkURiICi4ieLVuRrvzkymqds3C98HQGAfIIo_g6QoC6zdhRYIsM0sikBvg2HjVzZZ6chlye_sdXcgR2fP_ePALuEsDYAWh7AD25u3CvUSKNNcD2BVjMYD94eHJl9NB-NEwCLaAx9Pht1-QuBR3
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkYAL4k2ggJHghKwmdmI7B4R4VVva7WkRe7P8SrvSKln2Adr-Jy78EH4TYydZWIR66zV2HGf8eWY-P2YQesGNNYW3nlQUhiG3vCCl9JJwW4E1YE67uA45POGDz_mncTHeQT_6uzDhWGWvE6Oido0Na-T7DAwbkAPBxZvZVxKyRoXd1T6FRguLI7_-DpRt8frwA4zvS0oPPo7eD0iXVYDYvBRLUhXCM5FW2nlZZlVVpanJMmdlYaQ1nBlDvedVXlCnmbUFLV3ONNWWAZXggkGzV9BVsLtp4HpivOF3mZBp2d_LkXx_Af0VlIARJGGmpOR8y_bFFAH_82v_PZ75l707uIVudo4qftsi6zba8fUddG3YbcXfRV9-_SThNFU9qXG8fgI-KwYhNfDtEFWx9gToPgDH4dlqCgV6vsZnwHrn8cx8U-NvE41Pp2tAYoiKgqEdQOPiHhpdhjzvo926qf1DhIXVXFfgT4WMyNJUMgd65aUGAIGWMFmCsl58ynYRzEMijamKTEZy1YpcgchVFLk6T9CrzTuzNn7HhbXfhVHZ1Ayxt-ODZn6quqmsDC-ttEKDKnO5o1I766jJqCkdZfALCdrrx1R1CmGh_sA3Qc83xTCVw_6Mrn2zCnWAbYPOLYsEPWghsOkJK1NwXPM0QXILHFtd3S6pJ2cxXHi4JAZuJ3t0cb-eoeuD0fBYHR-eHD1GN2jErSCU7aHd5Xzln4DztTRPI-QxUpc8xX4DdDVGiw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%CE%B2-catenin+mediates+monocrotaline-induced+pulmonary+hypertension+via+glycolysis+in+rats&rft.jtitle=BMC+cardiovascular+disorders&rft.au=Meng%2C+Hui&rft.au=Deng%2C+Yan&rft.au=Liao%2C+Juan&rft.au=Wu%2C+Dan-Dan&rft.date=2024-07-23&rft.issn=1471-2261&rft.eissn=1471-2261&rft.volume=24&rft.issue=1&rft.spage=381&rft_id=info:doi/10.1186%2Fs12872-024-04000-z&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2261&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2261&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2261&client=summon